Stool microbiome and metabolome differences between colorectal cancer patients and healthy adultsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared stool microbiome composition and metabolite profiles between 11 colorectal cancer patients and 10 healthy adults. Samples were collected before colon resection surgery at a hospital in Fort Collins, Colorado.
How was it studied?
The V4 region of the 16s rRNA gene was pyrosequenced to profile bacterial communities. Short chain fatty acids and global stool metabolites were extracted and measured by Gas Chromatography Mass Spectrometry.
What did they find?
Overall microbial community structure did not differ significantly by disease state, but butyrate producing genera were under represented in cancer patients, while the mucin degrading species Akkermansia muciniphila was about 4 fold higher (p<0.01). Healthy adults had proportionately more butyrate, poly and monounsaturated fatty acids, and ursodeoxycholic acid, while cancer patients had more acetate and amino acids (p<0.01).
Why it matters
Correlations between specific bacteria and metabolites point to microbial functions that may shape the colorectal cancer environment. The authors suggest integrated microbiome and metabolome profiling could help identify chemopreventive and therapeutic targets.